New York, NY, United States

Time filter

Source Type

CAMBRIDGE, Mass. & DUBAI, United Arab Emirates--(BUSINESS WIRE)--GenePeeks, Inc., a computational genomics company focused on transforming genetic disease risk analysis, and Alliance Global Group (AGBL) today announced a new partnership to bring GenePeeks’ Virtual Progeny Analytics (VPA) technology platform to select markets in the Middle East and Africa. AGBL is the largest biomedical gateway in these markets. This collaboration marks another international market for the GenePeeks Preconception Screen, which identifies combined parental risk of passing on more than 1,000 serious genetic diseases. Under the terms of the agreement, AGBL will expand its genetic testing by offering GenePeeks Preconception Screen to patients, healthcare providers and laboratories in the Middle East and Africa. AGBL will also introduce additional applications of GenePeeks’ technology through partnerships with centers of excellence throughout the region. “We are honored to partner with Alliance Global to address the significant unmet need in these markets for comprehensive preconception screening,” said Anne Morriss, Co-Founder and Chief Executive Officer of GenePeeks. “AGBL’s regional breadth and market knowledge, combined with the analytic power of our advanced computational platform, will give more prospective parents the information and support they need to protect their future families. AGBL is another strong partner for our growing presence outside of the U.S.” Dr. Tamer Degheidy, Group CEO at Alliance Global stated, “GenePeeks Preconception Screen is an important addition to our growing portfolio of genetic tests, and we’re excited to offer this comprehensive, state-of-the art approach, which reduces the population biases that are associated with traditional carrier screening. It is the first step in our shared mission to transform gene-based clinical applications using GenePeeks’ core technology platform.” About GenePeeks’ Technology GenePeeks’ comprehensive approach, called Virtual Progeny Analytics (VPA), uniquely integrates simulated DNA information from two genetic participants to predict the future genome of a child prior to conception. For every mutation in these hypothetical genomes, the company computes a proprietary Variant Gene Dysfunction (VGD) score that predicts gene function and associated disease risk. This next generation approach allows GenePeeks to cover an expanded number of diseases with increased sensitivity and evaluate variants that may remain uncharacterized by other genetic tests, while avoiding the confusion and anxiety that can be associated with carrier testing. In contrast to carrier screening, which identifies parental carrier status, GenePeeks focuses on a future child’s true risk of disease inheritance. GenePeeks offers this physician-ordered service through its CLIA certified clinical laboratory. About GenePeeks GenePeeks is a computational genomics company focused on identifying inherited disease risk in future generations. GenePeeks’ patented technology digitally combines the genetic information of two potential parents, simulating the complex genetic interactions that occur naturally in human reproduction. The company’s proprietary platform creates and analyzes thousands of Virtual Progeny to uncover disease risk that cannot be seen with alternative screening tools. GenePeeks offers this physician-ordered service through its CLIA certified clinical laboratory. GenePeeks is privately held, with corporate offices in Cambridge, Mass. For more information, visit www.genepeeks.com GenePeeks’ next-generation screening technology is available today. For more information about becoming a partner, please contact support@genepeeks.com About Alliance Global Group (AGBL) The AGBL Group of companies is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MENA region. The group employs dedicated teams of product and applications specialists, and has many offices across the region offering distribution, consulting and product development services to world-renowned manufacturers of biomedical technologies. The group’s stated mission is to improve the lives of the region’s inhabitants through novel biomedical technologies and products. For more information, please visit: www.agbl.net


A system, device and method for receiving multiple aligned genetic sequences obtained from genetic samples of multiple organisms of one or more different species. A measure of evolutionary variation may be computed for one or more alleles at each of one or more aligned genetic loci. The aligned genetic loci in the multiple organisms may be derived from one or more common ancestral genetic loci or may be otherwise related. The measure of evolutionary variation may be a function of variation in alleles at corresponding aligned genetic loci in the multiple aligned genetic sequences. One or more likelihoods may be computed that an allele mutation at each of the one or more genetic loci in a simulated virtual progeny will be deleterious based on the measure of evolutionary variation of alleles at the corresponding aligned genetic loci for the multiple organisms.


News Article | February 28, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GenePeeks, Inc., a computational genomics company focused on transforming genetic disease risk analysis, today announced partnerships with two leading fertility organizations: The Donor Solution, an independent egg donation agency, and 3 Sisters Surrogacy, a gestational carrier service. Through these partnerships, more prospective parents will have access to GenePeeks’ proprietary preconception genetic screening test, which assesses combined parental risk of passing on more than 1,000 serious genetic diseases. GenePeeks’ comprehensive approach, called Virtual Progeny Analytics (VPA), uniquely integrates simulated DNA information from two genetic participants to predict the future genome of a child prior to conception. For every mutation in these hypothetical genomes, the company computes a proprietary Variant Gene Dysfunction (VGD) score that predicts gene function and associated disease risk. This next generation approach allows GenePeeks to cover an expanded number of diseases with increased sensitivity and evaluate variants that may remain uncharacterized by other genetic tests, while avoiding the confusion and anxiety that can be associated with carrier testing. In contrast to carrier screening, which identifies parental carrier status, GenePeeks focuses on a future child’s true risk of disease inheritance. GenePeeks offers this physician-ordered service through its CLIA certified clinical laboratory. Over the last ten years, The Donor Solution has helped over 1,000 families to have children, with a success rate of over 82% for first time donors. 3 Sisters Surrogacy provides exceptional support for the increasing number of individuals seeking a gestational carrier to build their family. Clients using the services of either agency will be able to use the GenePeeks test to make more informed reproductive decisions with increased confidence. In addition, The Donor Solution’s donors who have completed the pre-test protocols will be identified as “GenePeeks Ready,” saving prospective parents precious time in their fertility journey. “We are thrilled to partner with The Donor Solution and 3 Sisters Surrogacy, two organizations that share our unrelenting commitment to provide outstanding support on the complicated path of starting a family,” said Anne Morriss, Co-founder and Chief Executive Officer of GenePeeks. “In addition to reaching more families, these collaborations will allow us to expand our physician network and increase patient access to our next generation technology.” Mary Fusillo, Founder and Executive Director of The Donor Solution and Chief Executive Officer of 3 Sisters Surrogacy, stated, “At The Donor Solution and 3 Sisters Surrogacy, we are committed to providing our clients with the highest quality care possible. Our partnership with GenePeeks is an important step in ensuring that our intended families can protect the future health of their children with access to the most advanced preconception risk screening available.” About GenePeeks GenePeeks is a computational genomics company focused on identifying inherited disease risk in future generations. GenePeeks’ patented technology digitally combines the genetic information of two potential parents, simulating the complex genetic interactions that occur naturally in human reproduction. The company’s proprietary platform creates and analyzes thousands of Virtual Progeny to uncover disease risk that cannot be seen with alternative screening tools. GenePeeks offers this physician-ordered service through its CLIA certified clinical laboratory. GenePeeks is privately held, with corporate offices in Cambridge, Mass. For more information, visit www.genepeeks.com. GenePeeks’ next-generation screening technology is available today. For more information about becoming a partner, please contact support@genepeeks.com. About The Donor Solution The Donor Solution is a leading egg donor agency in the southwest United States. Known for providing exceptional egg donors, the agency recruits outstanding young women for their program. Founded in 2007 by Mary M. Fusillo, RN, BSN, MS, the agency has helped over 1,000 couples reach their goal of becoming parents. With over 25 years of nursing and hospital management experience, Mary and her team are committed to reducing the stress of the fertility journey while delivering the highest standard of care to both donors and recipients. The organization has offices in Houston and Dallas, Texas and Phoenix, Arizona, with satellite offices in Austin, Texas and Los Angeles/Beverly Hills, California. For more information, visit thedonorsolution.com. About 3 Sisters Surrogacy 3 Sisters Surrogacy is a gestational carrier program dedicated to providing intended parents with the highest level of competence and professionalism. Chief Executive Officer Mary M. Fusillo, RN, BSN, MS has over 16 years of third party parenting experience and donor recruitment, and Chief Scientific Officer Sunday Crider, Ph.D., has worked for 13 years as an IVF embryologist and laboratory director. This combined experience is unique in the industry and has allowed the organization to provide the highest standard of service to all clients. Corporate offices are located in Houston, Texas, with satellite offices in Dallas, Texas and Phoenix, Arizona. For more information, visit 3sisterssurrogacy.com.


News Article | February 15, 2017
Site: www.prweb.com

Executive search firm, Slone Partners, announces the placement of Matt Posard, as President and Chief Commercial Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics executive with extensive commercialization experience. GenePeeks is a computational genomics company focused on identifying inherited disease risk in future generations. In his new role, Matt will be responsible for leading the commercialization of its products and services as the company enters its next important growth phase. “We are grateful to the talented team at Slone Partners for successfully helping us fill this critical role,” said Anne Morriss, Co-founder and Chief Executive Officer of GenePeeks. “Matt has an outstanding track record of commercializing novel technologies, which is instrumental to our growth and success of our mission to help reduce a child’s risk of inheriting a genetic disease.” Prior to joining GenePeeks, Mr. Posard has held several leadership roles with innovative organizations including Illumina, Alere and Trovagene. He received a Bachelor of Arts degree in Quantitative Economics and Decision Science from the University of California, San Diego. Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for the diagnostics, life science tools, clinical trials, contract research, healthcare information technology and laboratory testing industries with offices in Boston, Washington, D.C. and San Francisco.


Methods and systems for assessing the probabilities of the expression of one or more traits in progeny are described.


A device, system and method for predicting gene-dysfunction caused by a genetic mutation in the genome of an organism. A neural network may comprise multiple nodes respectively associated with multiple different gene-dysfunction metrics and multiple different confidence weights. The neural network may combine the multiple gene-dysfunction metrics according to the respective associated confidence weights to generate one or more likelihoods that a genetic mutation causes gene-dysfunction in organisms. In a training-phase, the neural network may be trained using an input data set including genetic mutations to generate new gene-dysfunction metrics and new associated confidence weights that optimize the neural network based on a cost factor. In a run-time phase, a genetic mutation may be identified and one or more likelihoods may be computed that the identified genetic mutation causes gene-dysfunction in the organism based on the new gene-dysfunction metrics and the associated new confidence weights of the neural network.


A system, device and method for receiving multiple aligned genetic sequences obtained from genetic samples of multiple organisms of one or more different species. A measure of evolutionary variation may be computed for one or more alleles at each of one or more aligned genetic loci. The aligned genetic loci in the multiple organisms may be derived from one or more common ancestral genetic loci or may be otherwise related. The measure of evolutionary variation may be a function of variation in alleles at corresponding aligned genetic loci in the multiple aligned genetic sequences. One or more likelihoods may be computed that an allele mutation at each of the one or more genetic loci in a simulated virtual progeny will be deleterious based on the measure of evolutionary variation of alleles at the corresponding aligned genetic loci for the multiple organisms.


A system, device and method for receiving multiple aligned genetic sequences obtained from genetic samples of multiple organisms of one or more different species. A measure of evolutionary variation may be computed for one or more alleles at each of one or more aligned genetic loci. The aligned genetic loci in the multiple organisms may be derived from one or more common ancestral genetic loci or may be otherwise related. The measure of evolutionary variation may be a function of variation in alleles at corresponding aligned genetic loci in the multiple aligned genetic sequences. One or more likelihoods may be computed that an allele mutation at each of the one or more genetic loci in a simulated virtual progeny will be deleterious based on the measure of evolutionary variation of alleles at the corresponding aligned genetic loci for the multiple organisms.


Methods and systems for assessing the probabilities of the expression of one or more traits in progeny are described.


In accordance with an embodiment of the invention, a system and method is provided for determining a probability of a progeny having one or more phenotypes Ph_(j )each associated with a single gene Q_(j). A score sip may be assigned to each allele hip at a plurality of genetic loci (i) in a haploid genome profile H^(p )of a parent (p). A plurality (Nj) of the alleles hkp (k=1, . . . , Nj) associated with the gene Q_(j )may be identified. The scores sip may be mapped or indexed to gene-specific scores j,kp associated with gene Q_(j )for the plurality of (Nj) alleles hkp. A probability may be computed for altering the gene product from gene Q_(j )in a progeny of the parent (p) to be a function of the gene-specific scores j,kp.

Loading GenePeeks collaborators
Loading GenePeeks collaborators